DexCom, Inc. (DXCM) Debt to Assets Ratio: 0.22%
The debt to assets ratio for DexCom, Inc. (DXCM) is 0.22% as of Wednesday, June 10, 2026.
DXCM Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.22%
DXCM Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| DexCom, Inc. (DXCM) | — | 0.22% |
| Biogen Inc. (BIIB) | $29.00B | 0.24% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 0.54% |
| Veeva Systems Inc. (VEEV) | $26.73B | 0.01% |
| Centene Corporation (CNC) | $31.94B | 0.24% |
| Zoetis Inc. (ZTS) | $34.20B | 0.61% |
| Waters Corporation (WAT) | $23.83B | 0.29% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 0.63% |
| BioNTech SE (BNTX) | $21.81B | 0.01% |
| Agilent Technologies, Inc. (A) | $37.17B | 0.26% |
Leverage Ratios Comparison
Debt/Assets
0.2%
Debt/Equity
0.51
Current Ratio
1.88
Interest Coverage
49.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
DexCom, Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for DexCom, Inc. (DXCM)?
- The debt to assets ratio for DXCM stock is 0.22%.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach